Despite widespread clinical and molecular heterogeneity, therapeutic inhibition of BCR signaling using the Bruton tyrosine kinase (BTK) inhibitor ibrutinib14 has remarkable efficacy in essentially all patients with CLL. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.